Ocuphire Pharma, Inc. OCUP
1.17 0.00 (+0.00%)
At closeOct 23, 2024, 4:00 PM EDT
1.07 Day range 1.36
52-week range unavailable
News
prnewswire.com The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C. , Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture…
benzinga.com Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal On Wednesday, Ocuphire Pharma, Inc. OCUP announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).
businesswire.com Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics. Click here to…
globenewswire.com Ocuphire Pharma Announces Acquisition of Opus Genetics Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations
globenewswire.com Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile Published data from two Phase 3 clinical trials…
globenewswire.com UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following…
zacks.com Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates Ocuphire Pharma, Inc. (OCUP) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
globenewswire.com Ocuphire Pharma to Present at Two Investor Conferences in August FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing…
globenewswire.com Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON…
globenewswire.com Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies…
globenewswire.com Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies…
globenewswire.com Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the…
globenewswire.com Ocuphire Pharma to Present at the Aegis Virtual Conference FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of…
globenewswire.com Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
globenewswire.com First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
globenewswire.com Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of…
globenewswire.com Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule…
investorplace.com 7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
globenewswire.com Ocuphire Pharma to Present in the BIO CEO & Investor Conference FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and…
globenewswire.com Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing…
benzinga.com A Look Into Healthcare Sector Value Stocks 
benzinga.com Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.- benzinga.com Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Thursday, that it's featured on Webull Corporate Communications Service Platform.
- benzinga.com Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
benzinga.com Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com 68 Biggest Movers From Wednesday Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share.
- benzinga.com The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
benzinga.com 72 Biggest Movers From Yesterday Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.- benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 a.m. ET Friday, 62 stocks made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 38 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 192 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday During the morning session on Monday, 372 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Before 10 a.m. ET Friday, 82 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 375 companies hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning session, 286 stocks hit new 52-week highs.